Krsnaa Diagnostics Recovers ₹130 Cr Govt Dues, Posts 4% Revenue Rise

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAbhay Singh|Published at:
Krsnaa Diagnostics Recovers ₹130 Cr Govt Dues, Posts 4% Revenue Rise
Overview

Krsnaa Diagnostics reported Q3 FY'26 revenue of INR 1,812 million, up 4% YoY, significantly boosted by a INR 130 crore recovery of government dues. Normalized EBITDA reached INR 484 million (27% margin), and normalized PAT stood at INR 168 million (9% margin). Margins were temporarily impacted by expansion costs, which management termed a timing issue. The company highlights growth drivers from its Rajasthan project and a rapidly expanding B2C segment.

📉 The Financial Deep Dive

The Numbers:
Krsnaa Diagnostics Limited reported Q3 FY'26 revenue of INR 1,812 million, a 4% increase year-on-year. The company's reported EBITDA stood at INR 474 million, representing a 26% margin. Normalized EBITDA was reported at INR 484 million with a 27% margin. Normalized Profit After Tax (PAT) was INR 168 million, translating to a 9% margin. No QoQ figures were provided.

The Quality:
Profitability margins were temporarily influenced by cost absorption related to expansion initiatives, specifically the Rajasthan pathology rollout. Management characterized this as a timing issue rather than a structural one. A significant positive development was the recovery of over INR 130 crores in government dues during the quarter, which materially strengthened the company's cash position. Collections in Q3 were INR 100 crores higher than the same period last year, indicating improved working capital discipline. The company has maintained EBITDA and PAT positive status since inception.

The Grill:
Management faced investor queries regarding project execution timelines, particularly for the Rajasthan and Maharashtra projects. The Rajasthan project is expected to achieve breakeven in Q4 FY'26, with Maharashtra revenues anticipated in subsequent quarters. When questioned about margin pressures, management emphasized that cost absorption from expansion activities is a temporary phase.

🚩 Risks & Outlook

Specific Risks:
The company operates in a sector susceptible to seasonal industry softness. Temporary operational pauses were undertaken to accelerate the recovery of long-pending government receivables, highlighting a reliance on timely payments from government entities. Expansion initiatives, like the Rajasthan pathology rollout, introduce upfront costs and execution risks, though management views these as timing-related. The capital-intensive nature of its radiology-led PPP model requires significant upfront equipment investment, impacting near-term returns.

The Forward View:
Growth drivers for Krsnaa Diagnostics include the continued ramp-up of the Rajasthan project, which is projected to contribute approximately INR 200 crores in annualized revenue in FY'27. The B2C segment is a second engine of growth, demonstrating strong traction with retail revenue growing 8x year-on-year and touchpoints expanding. The launch of Apulki Healthcare Hospital in Pune signifies a strategic move into integrated tertiary care. Management aims for higher teens revenue growth in the base business (ex-B2C, ex-Rajasthan), with pathology contribution expected to rise to 65-70% of revenue.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.